• Explore /
  • Abstract
  • / Real-world treatment outcomes in patients with advanced renal cell carcinoma who receive axitinib plus pembrolizumab in the first-line setting in Canadian cancer centers.

Real-world treatment outcomes in patients with advanced renal cell carcinoma who receive axitinib plus pembrolizumab in the first-line setting in Canadian cancer centers.

Abstract Poster

Authors

null

Carissa Beaulieu

Department of Medical Oncology, University of Alberta, Cross Cancer Institute, Edmonton, AB, Canada

Carissa Beaulieu , Sunita Ghosh , Camilla Tajzler , McKayla Kirkpatrick , Vincent Castonguay , Lori Wood , Jeffrey Graham , Denis Soulieres , Rahul K. Bansal , Daniel Yick Chin Heng , Antonio Finelli , Simon Tanguay , Aly-Khan A. Lalani , Bimal Bhindi , Georg A. Bjarnason , Rodney H. Breau , Naveen S. Basappa

Organizations

Department of Medical Oncology, University of Alberta, Cross Cancer Institute, Edmonton, AB, Canada, Department of Oncology, University of Alberta, Edmonton, AB, Canada, McGill University Health Centre, Montréal, QC, Canada, School of Public Health, University of Alberta, Edmonton, AB, Canada, Medical Oncology, Centre Hospitalier Universitaire de Québec, Université Laval, Quebec City, QC, Canada, Division of Medical Oncology, Dalhousie University, Halifax, NS, Canada, Medical Oncology and Hematology, University of Manitoba, CancerCare Manitoba, Winnipeg, MB, Canada, Département Hématologie-Oncologie, Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada, Division of Urology, Department of Surgery, McMaster University, Hamilton, ON, Canada, Department of Oncology, Tom Baker Cancer Center, Calgary, AB, Canada, Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada, Division of Urology, Department of Surgery, McGill University, Montreal, QC, Canada, Department of Oncology, Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada, Southern Alberta Institute of Urology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada, Department of Surgery, University of Ottawa, Ottawa, ON, Canada, Department of Medical Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada

Research Funding

No funding sources reported

Background: The landscape of management of advanced renal cell carcinoma (aRCC) in the first line setting has changed dramatically over the past decade. Axitinib with Pembrolizumab (AP) is one of the combinations which demonstrated improved outcomes in the KEYNOTE 426 study. We report real-world outcomes and safety with this combination. Methods: The Canadian Kidney Cancer information system (CKCis) is a multi-institutional prospective RCC cohort. Patients ≥18 years with aRCC and clear cell histology who received AP as first-line therapy from January 1, 2017 to June 30, 2022 were included. Descriptive and actuarial statistics were reported for the following: progression free survival (PFS), overall survival (OS) and adverse events. Results: The cohort includes 222 patients.165 (74.3%) were male with a median age of 64.5 (37.0-87.7) years. Sixty-three (28.3%) patients were IMDC favourable-risk, 69 (31.0%) intermediate-risk, 45 (20.3%) poor-risk and 45 (20.2%) unknown. Median follow-up was 26.6 (range: 0.1 – 77.2) months. Of 222 patients, 119 discontinued treatment (53.6%) due to disease progression in 45.4% or toxicity in 29.4%. Median duration of treatment was 18.5 (range 0.1 to 72.4) months. PFS probability at 12 and 24 m was 63.8% and 49.9% respectively with a median PFS of 22.6 months (95% CI: 15.9-30.1). Survival probability at 12 and 24 m was 89.1% and 80.2% respectively with a median OS of 51.5 months (95% CI 38.0-NR). By IMDC criteria, intermediate risk median OS was 44.8 m (95% CI 41.5-61.6) and poor risk 33.6 m (18.5-NR). Most patients experienced toxicity requiring dose interruption/delay or discontinuation (n=180; 81.4%) The most common toxicities were diarrhea (73.3%), fatigue (54.4%), hepatotoxicity (50.0%), anorexia (26.1%), mucositis (22.2%), nausea (21.1%), palmar plantar erythrodysesthesia (15.6%), hypertension (13.3%), weight loss (13.3%) and proteinuria (11.7%). Others included pneumonitis (8.9%), thyroid dysfunction (6.7%) and colitis (4.4%). Conclusions: The real-world experience of patients with aRCC receiving AP in Canada is similar to the KEYNOTE-426 study in both outcomes and safety. These data continue to support its position as a standard of care in the first line setting for aRCC. Longer follow up and characterization of these patients is warranted.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2024 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Renal Cell Cancer; Adrenal, Penile, and Testicular Cancers

Track

Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer

Sub Track

Quality of Care/Quality Improvement and Real-World Evidence

Citation

J Clin Oncol 42, 2024 (suppl 4; abstr 382)

DOI

10.1200/JCO.2024.42.4_suppl.382

Abstract #

382

Poster Bd #

F6

Abstract Disclosures

Similar Abstracts

First Author: Daniel M. Geynisman

First Author: Marné Garretson

First Author: Syvart Dennen

First Author: Viktor Grünwald